Abstract
The authors evaluated the clinical efficacy and safety of the antiviral and immunomodulatory drug Isoprinosine (inosine pranobex, Teva Pharmaceutical Industries, Ltd) in the treatment of bronchopulmonary diseases in children. One hundred and fifty-two children with acute respiratory diseases and an exacerbation of recurrent respiratory diseases were followed up. The use of Isoprinosine in their combined treatment showed both positive clinical changes and a better immunogram.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Adjuvants, Immunologic / therapeutic use*
-
Adolescent
-
Child
-
Child, Preschool
-
Environmental Exposure / adverse effects*
-
Environmental Illness / drug therapy*
-
Environmental Illness / epidemiology
-
Environmental Illness / immunology
-
Follow-Up Studies
-
Humans
-
Immunomodulation / drug effects
-
Immunomodulation / immunology*
-
Inosine Pranobex / therapeutic use*
-
Morbidity / trends
-
Respiratory Tract Diseases / drug therapy*
-
Respiratory Tract Diseases / epidemiology
-
Respiratory Tract Diseases / immunology
-
Russia / epidemiology
Substances
-
Adjuvants, Immunologic
-
Inosine Pranobex